Pharmaceutical News

RSS

Researchers find Aspergillus as interesting target for discovery of novel drugs

The fungus Aspergillus fumigatus produces a group of previously unknown natural products. With reference to plant isoquinoline alkaloids, these substances have been named fumisoquins.

28 May 2016

Surrogate endpoints for cancer drug approval often lack formal empirical verification

Surrogate endpoints used to support the majority of new cancer drugs approved in the U.S. often lack formal study, according to the authors of a study published in the June issue of Mayo Clinic Proceedings.

28 May 2016

Reducing use of opioid medications possible, but challenging

A team of researchers at the University of Colorado School of Medicine and the VA Eastern Colorado Health Care System recently surveyed patients to understand barriers to reducing the use of opioids to manage chronic pain. The results of those interviews are published in the current issue of the journal Pain Medicine.

28 May 2016

Inadequate monitoring places post-operative patients at risk for opioid-induced respiratory depression

Nearly 75 percent of hospitalized patients receiving opioids for pain management are not monitored according to hospital guidelines.

28 May 2016

Pharmacist suggests education as foremost strategy to control opioid abuse

Technologies that make it harder for people to abuse opioids - like doctoring pills so that they produce unpleasant side effects if broken, crushed or injected -- likely will have limited effectiveness in stemming the global epidemic of opioid abuse, according to Adam Kaye, a professor of pharmacy at University of the Pacific.

28 May 2016

Overcoming barriers to move beyond race-based treatment decisions

Prescribing certain medications on the basis of a patient's race has long come under fire from those uneasy with using race as a surrogate for biology when treating disease.

28 May 2016

Vismodegib drug shows no addded benefit in advanced or symptomatic metastatic BCC patients

Vismodegib (trade name: Erivedge) has already been approved since 2013 for the treatment of patients with locally advanced basal cell carcinoma (BCC) or symptomatic metastatic BCC and has already undergone an early benefit assessment according to the Act on the Reform of the Market for Medicinal Products.

28 May 2016

Axumin approved for use in PET scans in patients with recurrent prostate cancer

The U.S. Food and Drug Administration today approved Axumin, a radioactive diagnostic agent for injection. Axumin is indicated for positron emission tomography (PET) imaging in men with suspected prostate cancer recurrence based on elevated prostate specific antigen (PSA) levels following prior treatment.

28 May 2016

Zinbryta gets FDA approval for treating adults with relapsing forms of MS

The U.S. Food and Drug Administration today approved Zinbryta (daclizumab) for the treatment of adults with relapsing forms of multiple sclerosis (MS). Zinbryta is a long-acting injection that is self- administered by the patient monthly.

28 May 2016

Applying deep neural networks to predict pharmacologic properties of drugs and drug repurposing

Deep learning, frequently referred to as artificial intelligence, a branch of machine learning utilizing multiple layers of neurons to model high-level abstractions in data, has outperformed humans in tasks including image, text and voice recognition, autonomous driving and others, and is now being applied to drug discovery and biomarker development.

28 May 2016

Researchers develop new drugs for melanoma

Finding new, more effective and personalised treatments for cancer is the challenge of many researchers. A challenge that has been successfully met by a team from Inserm led by Stéphane Rocchi, which has just synthesised and developed new drugs for melanoma.

28 May 2016

Brivaracetam drug shows no added benefit for epilepsy

Brivaracetam (trade name: Briviact) has been approved since January 2016 as add-on therapy for adolescents from the age of 16 years and adults with epileptic seizures. The German Institute for Quality and Efficiency in Health Care now examined in an early benefit assessment whether this drug offers an added benefit for patients in comparison with the appropriate comparator therapy.

28 May 2016

Study identifies potential new treatment for subset of gastric cancer patients

Testing cancers for 'addiction' to a gene that boosts cell growth can pick out patients who may respond to a targeted drug under development, a major new study reports.

28 May 2016

Organic chemists succeed in synthesizing 3,6-Dihydro-2H-pyran derivatives with high enantiomeric purity

The pyran ring is present in so many useful compounds, such as pharmaceuticals (antibiotics, anti-infectives, cardiovascular agents, neurological modulators, anti-allergic, anti-asthmatic, anti-inflammatory agents, reproductive and genitourinary agents, growth promoters and antidiabetic agents), veterinary products, agrochemicals, toxins, polymers and additives, photosensitizers and photoinitiators, surfactants, food products, dyes and pigments.

28 May 2016

NR supplements can reduce diabetes-related complications in mice

A naturally occurring vitamin, nicotinamide riboside (NR), can lower blood sugar levels, reduce fatty liver, and prevent peripheral nerve damage in mouse models of prediabetes and type 2 diabetes (T2D), according to a new study by researchers at the University of Iowa and the Iowa City VA Health Care System.

27 May 2016

First buprenorphine implant for opioid dependence treatment gets FDA approval

The U.S. Food and Drug Administration today approved Probuphine, the first buprenorphine implant for the maintenance treatment of opioid dependence. Probuphine is designed to provide a constant, low-level dose of buprenorphine for six months in patients who are already stable on low-to-moderate doses of other forms of buprenorphine, as part of a complete treatment program.

27 May 2016